These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, Schalken JA. Prostate; 2010 Jan 01; 70(1):10-6. PubMed ID: 19708043 [Abstract] [Full Text] [Related]
8. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. Ochiai A, Trpkov K, Yilmaz A, Donnelly B, Babaian RJ. J Urol; 2007 Mar 01; 177(3):907-10. PubMed ID: 17296373 [Abstract] [Full Text] [Related]
9. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA. Eur Urol; 2008 Nov 01; 54(5):1081-8. PubMed ID: 18602209 [Abstract] [Full Text] [Related]
10. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO. J Urol; 2005 Sep 01; 174(3):898-902. PubMed ID: 16093983 [Abstract] [Full Text] [Related]
11. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ. J Urol; 2010 Feb 01; 183(2):534-8. PubMed ID: 20006883 [Abstract] [Full Text] [Related]
12. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ. J Urol; 2005 Dec 01; 174(6):2164-8, discussion 2168. PubMed ID: 16280756 [Abstract] [Full Text] [Related]
13. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. Kassouf W, Nakanishi H, Ochiai A, Babaian KN, Troncoso P, Babaian RJ. J Urol; 2007 Jul 01; 178(1):111-4. PubMed ID: 17499289 [Abstract] [Full Text] [Related]
15. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF. J Urol; 2013 Jul 01; 190(1):64-9. PubMed ID: 23416644 [Abstract] [Full Text] [Related]
16. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M. BJU Int; 2012 Feb 01; 109(3):360-6. PubMed ID: 21883822 [Abstract] [Full Text] [Related]
18. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. Clin Cancer Res; 2007 Feb 01; 13(3):939-43. PubMed ID: 17289888 [Abstract] [Full Text] [Related]